Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan
Takashi Kadowaki
Masakazu Haneda
Hiroshi Ito
Kazuyo Sasaki
Yuka Yamada
10.6084/m9.figshare.11993877.v2
https://adisjournals.figshare.com/articles/figure/Long-Term_Safety_and_Efficacy_of_Teneligliptin_in_Elderly_Type_2_Diabetes_Patients_Subgroup_Analysis_of_a_3-Year_Post-Marketing_Surveillance_in_Japan/11993877
<p>The above summary slide and plain language summary represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).<br></p>
<p>© The authors, CC-BY-NC 2020.<b>
</b></p>
2020-04-14 15:28:26
Diabetes
Dipeptidyl peptidase-4 inhibitor
Elderly patients
Post-marketing surveillance
Real-world
Teneligliptin
Type 2 diabetes mellitus
Plain Language Summary